2021 - Cancer Currents Blog
-
A recent study quantified the risk of osteonecrosis of the jaw for patients who take zoledronic acid to manage complications from cancer that has spread to the bone. The study also examined risk factors for osteonecrosis of the jaw in these patients.
-
FDA’s recent approval of relugolix (Orgovyx) is expected to affect the treatment of men with advanced prostate cancer. A large clinical trial showed that relugolix was more effective at reducing testosterone levels than another common treatment.
-
Obesity changed the relationship between cancer cells and nearby immune cells in ways that helped tumors survive and grow, a study in mice showed. But altering tumor cell metabolism helped immune cells once again recognize and infiltrate tumors.
-
Cancer cells that are leftover after treatment can go into a “dormant” state for years. A new study in mice suggests that stress hormones may trigger a chain reaction that wakes up dormant cancer cells, causing tumors to form again.
-
With the Cancer Moonshot having reached its midway point, NCI Director Dr. Ned Sharpless and Deputy Director Dr. Dinah Singer provide a report on the progress to date and future directions for this ambitious initiative to accelerate progress against cancer.
-
The drug abemaciclib (Verzenio) may be a new treatment option for people with the most common type of breast cancer, with new study findings suggesting that it can reduce the risk of the cancer returning.